BioRestorative Therapies (BRTX) SEC Filings: History & Chart

BioRestorative Therapies, Inc.(BRTX)

Biotechnology · Melville, NY

$2.17-0.07 (-3.13%)

Delayed quote: Oct 6, 2026, 10:22 AM EDT

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. is a life sciences company dedicated to developing regenerative medicine products and therapies. Their approach primarily utilizes adult stem cell protocols to address two key areas: disc/spine disease and metabolic disorders. Within their disc/spine program, known as brtxDisc, the company's leading cell therapy candidate is BRTX-100. This treatment involves culturing mesenchymal stem cells harvested from a patient's own bone marrow (autologous) to provide a non-surgical solution for painful lumbosacral disc conditions. BRTX-100 has successfully completed Phase 1 clinical trials. The company is also advancing its Metabolic Program, named ThermoStem, which is currently in the preclinical stage. This cell-based therapy targets obesity and other metabolic ailments by employing brown adipose-derived stem cells to generate brown adipose tissue. Beyond these core programs, BioRestorative Therapies also offers an investigational curved needle device designed for delivering cells and various therapeutic materials to the spine and discs. The company fosters strategic research and development partnerships, including agreements with Rohto Pharmaceutical Co., Ltd., Pfizer, Inc., and the University of Pennsylvania. Founded in 1997 and headquartered in Melville, New York, the company was initially known as Stem Cell Assurance, Inc., before rebranding to BioRestorative Therapies, Inc. in August 2011.

Melville, NY

14 employees

www.biorestorative.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Katharyn Field

View full financials

Form	Filing Date	Accepted	Document
8-K	Sep 11, 2026	Sep 11, 2026	View filing
8-K/A	Sep 10, 2026	Sep 10, 2026	View filing
8-K	Sep 2, 2026	Sep 2, 2026	View filing
8-K	Sep 2, 2026	Sep 1, 2026	View filing
8-K	Aug 25, 2026	Aug 25, 2026	View filing
NT 10-Q	Aug 14, 2026	Aug 14, 2026	View filing
8-K	Aug 14, 2026	Aug 14, 2026	View filing
SC 13G/A	Aug 3, 2026	Aug 3, 2026	View filing
3	Jul 30, 2026	Jul 30, 2026	View filing
3	Jul 24, 2026	Jul 24, 2026	View filing
8-K	Jul 16, 2026	Jul 16, 2026	View filing
3	Jun 18, 2026	Jun 18, 2026	View filing
3	Jun 18, 2026	Jun 18, 2026	View filing
3	Jun 17, 2026	Jun 17, 2026	View filing
8-K	Jun 12, 2026	Jun 12, 2026	View filing
8-K	Jun 12, 2026	Jun 12, 2026	View filing
8-K	May 29, 2026	May 29, 2026	View filing
SC 13G/A	May 15, 2026	May 15, 2026	View filing
10-Q	May 14, 2026	May 14, 2026	View filing
8-K	May 1, 2026	May 1, 2026	View filing
424B3	Apr 30, 2026	Apr 30, 2026	View filing
EFFECT	Apr 28, 2026	Apr 29, 2026	View filing
POS AM	Apr 27, 2026	Apr 27, 2026	View filing
8-K	Apr 23, 2026	Apr 23, 2026	View filing
POS AM	Apr 20, 2026	Apr 20, 2026	View filing
DEF 14A	Apr 13, 2026	Apr 13, 2026	View filing
PRE 14A	Apr 3, 2026	Apr 3, 2026	View filing
10-K	Mar 26, 2026	Mar 26, 2026	View filing
SC 13G/A	Feb 23, 2026	Feb 23, 2026	View filing
SC 13G	Feb 18, 2026	Feb 18, 2026	View filing

SEC Filings

Recent Filings